

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010351

International filing date: 28 March 2005 (28.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/556,474  
Filing date: 26 March 2004 (26.03.2004)

Date of receipt at the International Bureau: 29 April 2005 (29.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1310757

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*April 19, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/556,474**

**FILING DATE: *March 26, 2004***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/10351***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Please type a plus sign (+) inside this box → ☐

Revised PTO/SB/16 (8-00)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket No.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
George F.		VANDE WOUDE		Ada, Michigan	
Qian		XIE		Grand Rapids, Michigan	
David		WENKERT		East Lansing, Michigan	
Yuehai		SHEN		East Lansing, Michigan	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input checked="" type="checkbox"/> Customer Number		26694		26694	
OR		Type Customer Number here		PATENT TRADEMARK OFFICE	
<input checked="" type="checkbox"/> Firm or Individual Name		VENABLE LLP			
Address		P.O. Box 34385			
Address					
City		Washington	State	DC	ZIP 20043-9998
Country		U.S.A.	Telephone	202.344.4000	Fax 202.344.8300
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		13	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		5	<input type="checkbox"/> Other (specify)		Return Postcard
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
FILING FEE AMOUNT (\$)					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		22-0261	80.00		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

Date March 26, 2004

REGISTRATION NO. 33,949  
(if appropriate)

TYPED or PRINTED NAME Shmuel Livnat

Docket Number: 38345-201708

TELEPHONE 202-344-4000

### USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51, and is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Box Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#534793

VENABLE  
ATTORNEYS AT LAW

## **Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets**

### **BACKGROUND OF THE INVENTION**

#### **Field of the Invention**

5           The present invention in the field of cancer pharmacology is directed to novel agents, geldanamycin derivatives, that show inhibitory activity at femtomolar concentrations.

#### **Description of the Background Art**

Geldanamycin is an ansamycin natural product drug. GA and its derivatives have been shown to inhibit the growth of human carcinoma cells in a dose-dependent manner and have  
10   antitumor activity in breast, melanoma, and ovarian mouse xenograft models in athymic nude mice (6). These compounds work by reducing the intracellular concentration of a large number of tyrosine and serine kinase oncogene products, including Her2, Met, Raf, cdk4, and Akt (1,7,8). A recent study with prostate cancer cells found that GA stimulated degradation of Hif-1 $\alpha$ , suggesting that the drug may also inhibit vasculogenesis (9-11). GA drugs at nanomolar  
15   levels inhibit the function of the molecular chaperone HSP90, preventing proper folding of oncoproteins, thus promoting their destabilization and leading to inhibition of tumor growth (1, 12-14).

GA is not used clinically due to solubility and toxicity limitations, but 17-AAG (NSC.330507), a GA derivative that shows tumor inhibitory activity with less toxicity (15), is  
20   being evaluated in phase I-II clinical trials (16, 17). Another GA derivative in preclinical evaluation is 17-DMAG, which has greater water solubility and is available for oral delivery. The bioavailability of 17-DMAG is essentially 100% when given i.p., about twice that of orally delivered 17-AAG (18). 17-AG, a metabolite of 17-AAG, has equivalent biological activity as determined by the ability to decrease p185<sup>erbB2</sup> and is under development as a potential  
25   therapeutic (19). In breast cancer, both GA and 17-AAG can sensitize the cells to Taxol and doxorubicin-mediated apoptosis (20).

The SF/HGF-Met signal pathway has been widely accepted as playing an essential role in tumor proliferation, invasion, and metastasis. Met and its ligand, HGF/SF, contribute to tumorigenesis and metastasis in all types of solid tumors (21, 22), and the multiple activities of  
30   HGF/SF-Met signaling pathways leading to proliferation, invasion, angiogenesis, and cell

survival are well characterized (23-27). Previously, our lab discovered that GA and several derivatives inhibit urokinase-plasmin network at femtomolar concentrations only in MDCK cells.

Previous work from the present inventors' laboratory showed that only 4 out of over 30 geldanamycin (GA)-derived drugs provided by the NCI Anti-Neoplastic Drug Screen Program (NCI ADS) inhibited the activation of urokinase plasminogen activator (uPA)-plasmin by hepatocyte growth factor/scatter factor (HGF/SF) in MDCK cells at femtomolar concentrations (Ref. 1: Webb CP *et al.*, *Cancer Res.* 60: 342-3491). There drugs are referred to herein as "GafM" drugs versus drugs of the GA family drugs that show activity in the nanomolar range (referred to as "GanM" drugs).

10

### SUMMARY OF THE INVENTION

Some of the drugs listed in the publication by Webb *et al.* (*supra*) as supplied by the NCI-Ads were found not to be pure, leading to earlier incorrect interpretations. A study in collaboration with co-inventors Drs. David Wenkert and Yuehai Shen has resolved the problem of impurities in the original samples. The inventors synthesized the active GA derivatives. This is the first report that GA and certain derivatives have the same function in tumor cells through two independent experiments. By using the uPA assay as a method measuring uPA-plasmin network activity, it was found that GA and 17-AAG inhibit the network at femtomolar (fM) concentrations, as observed in MDCK cells (Figure 2). By contrast, in a basement membrane Matrigel® invasion assay, the number of GBM cells that penetrated through Matrigel® was increased almost 10-fold with HGF/SF treatment (100 ng/ml) relative to the control group; however, invasion was almost completely inhibited by GA at fM (Figure 3). Thus, these drugs are candidates for interfering with tumor cell invasion, and may be combined with surgery, conventional chemotherapy, or radiotherapy to prevent cancer cell invasion.

In parallel studies, the novel target of GAfM drugs was identified. Previously reported targets include HSP90, Grp94, and TRAP1 (tumor necrosis factor receptor-associated protein 1), and the therapeutic effects of the GA drug family are addressed mainly through HSP90 $\alpha$  (5). By using GA-coated Affigel beads, we discovered VDAC1 protein as a novel target that can bind to GAfM. VDAC1 is a group of proteins forming the aqueous pore on the mitochondrial outer membrane that elicit the crosstalk between mitochondria and the rest of the cell.

Recently, VDAC has been implicated in the early steps of mitochondria-dependent apoptosis (28). The discovery of VDAC1 as a novel target of GAfM leads to the new applications of GA drugs directed against apoptosis mechanisms and more. The VDAC1 structure with GA can provide new drug design. New anticancer drugs can be designed and the implication of apoptosis on GAfM activity explored.

The present inventors have synthesized and purified all of the compounds listed herein. Testing of these compounds has led to the conclusion that the most active geldanamycin derivatives are those in which the 17-methoxy group of geldanamycin has been replaced by an amino or an alkylamino group. In the case of the latter, the alkyl substituent may be itself derivatized, but it needs to be short.

Such active geldanamycin derivatives are exemplified by 17-amino-17-demethoxygeldanamycin, 17-(*N*-allylamino)-17-demethoxygeldanamycin, 17-[2-(dimethylamino)-ethylamino]-17-demethoxygeldanamycin, and 17-(2-chloroethyl)amino-17-demethoxygeldanamycin. Derivatives that had longer 17-alkylamino substituents were not active; the latter include 17-[6-(acetylamino)hexylamino]-17-demethoxygeldanamycin and 17-[6-(*N*-succinyl)hexylamino]-17-demethoxygeldanamycin. Additionally the 17,18-derivatized compound 7'-bromogeldanoxazinone was found to not be active.

Modifications to the ansa ring of geldanamycin [that is, the carbon atoms of the large ring of geldanamycin excluding those of the benzoquinone ring, in positions 1 through 15 of geldanamycin] resulted in derivatives that have activity only in the nanomolar range. Examples of this are esters of the 11-hydroxyl group of geldanamycin.

The list of the drugs and their femtomolar activity against invasion in GBM cells is disclosed herein.

### **BRIEF DESCRIPTION OF THE DRAWINGS**







(see next section)

**DESCRIPTION OF THE PREFERRED EMBODIMENTS**

and

**EXAMPLES**

The compounds that were synthesized and tested are described below.



Geldanamycin derivatives: Names, molecular weights and activities

Entry	NSC number	GVW code	YS code	Chemical Name (Abbr.)	Chemical name (Full)	M.W.	$\mu$ PA <sup>1</sup>
1	122750	GA		GA	geldanamycin	560.64	Yes
2	320877	F	YS1079	17-CEG	17-(2-chloroethyl)amino-17-demethoxygeldanamycin	608.12	Yes <sup>2</sup>
3	683659	Q	YS1080	17-DMAG	17-(dimethylaminoethyl)amino-17-demethoxygeldanamycin	616.75	Yes
4	330507	H	YS1057	17-AAG	17-allylamino-17-demethoxygeldanamycin	585.69	Yes
5	255109	V	YS1051	17-AG	17-amino-17-demethoxygeldanamycin	545.62	Yes
6	255105	B		BGX	7'-bromo-17-demethoxygeldanoxazone <sup>3</sup>	698.60	No
7	---		YS1025	17-AAHG <sup>4</sup>	17-(6-acetylaminohexyl)amino-17-demethoxygeldanamycin	686.84	No

<sup>1</sup> Yes = sample has activity at fM level; No = sample has activity only at nM level.

<sup>2</sup> Sample contaminated with ~10% geldanamycin.

<sup>3</sup> Reported name by K. L. Rinehart

<sup>4</sup> Affinity beads analog

\* National Cancer Institute designation



As before, GA, 17-AAG, 17-CEG, and 17-AG display GAfM activity, but other compound in Table 1 are different than those in the original report (1) due to unexpected impurities in some of the original samples tested. The most active geldanamycin derivatives are those in which the 17-methoxy group of geldanamycin has been replaced by an amino or an alkylamino group. In the case of the latter, the alkyl substituent may be itself derivatized, but it needs to be short. Such active geldanamycin derivatives are exemplified by 17-amino-17-demethoxygeldanamycin, 17-(*N*-allylamino)-17-demethoxygeldanamycin, 17-[2-(dimethylamino)-ethylamino]-17-demethoxygeldanamycin, 17-(2-chloroethyl)amino-17-demethoxygeldanamycin, and 17-(2-fluoro)ethylamino-17-demethoxygeldanamycin. Derivatives that had longer 17-alkylamino substituents were not active. The latter included 17-[6-(acetylamino)hexylamino]-17-demethoxygeldanamycin and 17-[6-(*N*-succinyl)hexylamino]-17-demethoxygeldanamycin. Additionally the 17,18-derivatized compound 7'-bromogeldanoxazinone was found to not be active.

**Table 1. High-activity GA derivatives (unpublished )**

NSC No.	Abbrev.	Chemical Name
122750	GA	Geldanamycin
320877	17-CEG	17-(2-chloroethyl)amino-17-demethoxygeldanamycin
255109	17-AG	17-amino-17-demethoxy-geldanamycin
683659	17-DMAG	17-(dimethylaminoethyl)amino-17-demethoxygeldanamycin
	17-FEG	17-(2-fluoro)ethylamino-17-demethoxygeldanamycin
330507	17-AAG	17-allylamino-17-demethoxy-geldanamycin

15

Modifications to the ansa ring of geldanamycin (that is, the carbon atoms of the large ring of geldanamycin excluding those of the benzoquinone ring, or positions 1 through 15 of geldanamycin) resulted in derivatives that have activity only in the nanomolar range. Examples of this are esters of the 11-hydroxyl group of geldanamycin. The uPA assay shows that after HGF/SF treatment (10 ng/ml), uPA activity is up-regulated. When MDCK cells are treated with these drugs, however, the uPA activity can be inhibited down to the femtomolar

20

level, suggesting a potential use for these drugs as uPA inhibitors (Figure 1). Radicicol is a chemical which reportedly works the same as GA drugs, but it only shows nanomolar level activity against uPA-plasmin proteolysis in this assay and, therefore, it served as a negative control.

5

**Discovery that human glioblastoma and sarcoma cells are also sensitive to GAfM.**

Previous work from the present inventors' lab and others (2,3,4) has shown that GBM cell lines express Met and HGF/SF and display strong proliferative or invasive responses to HGF/SF (2). In screening several human GBM tumor cell lines using the uPA assay, one  
10 highly invasive line discovered to display GAfM inhibition of the uPA plasmin proteolysis network (Figure 2), as observed in MDCK cells (1) (Figure 1).

After treatment with HGF/SF (10 ng/ml), uPA activity was up-regulated (a control shows the activity is inhibited by HGF/SF-neutralizing mAb in GBM-DBTRG cells (Figure  
15 1).

The striking result was that GA and 17-AAG inhibit HGF/SF-induced uPA activity at  $10^{-13}$  M in DBTRG cells where Met expression is unaffected (Figure 3), while a GA derivative such as Macbecin II inhibited only in the nM range where Met expression is markedly inhibited (1) (Figure 2).

20

Human SK-LMS-1 leiomyosarcoma cells display similar, though somewhat less active, sensitivity to the GAfM drugs, illustrating that this is a more common target in tumor cells.

In addition to inhibition of the uPA-plasmin activity, the present inventors discovered  
25 that HGF/SF-mediated invasion through basement membrane (Matrigel®) was also blocked by the GAfM drugs at fM concentrations (Figure 3). The number of GBM cells that penetrated through Matrigel was significantly increased with HGF/SF treatment (100 ng/ml) when compared with the control group.

However, this invasion was dramatically inhibited by GAfM treatment down to a concentration of  $10^{-15}$  M and 17-AAG worked as well (data not shown). This argues in favor of the present inventors conception that GAfM have promise for interfering with GBM tumor cell invasion *in vivo*.

5

#### **Identification of Novel GA Targets**

With the collaboration of co-inventors, Dr. David Wenkert and Yuehai Shen, novel GA targets were discovered in addition to the best known target, HSP90 (5).

GA was coated on the Affigel® beads and proteins that bound to GA could be  
10 recognized in pull-down experiments.

Results of the GA pull-down assays using DBTRG cells with control beads (lane 1) or GA beads (lanes 2-4) are shown in Figure 4.

In the indicated samples, 24 hours before cell lysis, GA or 17AAG was added to the cell cultures. This allowed us testing for GA bead competition in the pull-down assay.

15 In addition to HSP90, which is the previously reported GA target (5), the present inventors identified new potential GA target position candidates.

Candidate 2 is VDAC1 (voltage-dependent anion channel, also known as porin), a mitochondrial membrane protein which has been implicated in mitochondrial-related apoptosis in normal and tumor cells (28). The same pull-down assay was performed on  
20 MDCK cells and showed the same results.

*Mitochondria enrichment for porin (Figure 5).*

VDAC1 has been found on the membrane of mitochondria.

Therefore, mitochondria from MDCK cells in lysis buffer were subjected to pull-down assays using GA affinity beads.

5           Lanes 1 and 2 are MDCK total cell lysates pulled down by control or GA affinity beads, as described above, followed by blotting with HSP90 $\alpha$  and VDAC1 antibody acting as the negative and positive controls, respectively. Lanes 3–5 are samples generated from mitochondria enrichment using a Mitochondria Isolation Kit (Sigma Cat. Mito-Iso1).

10           Cells were cultured in 150x25-mm dishes. Ten dishes of cells were lysed with the buffer A (50 mM Hepes, pH 7.5, 1 M mannitol, 350 mM sucrose, 5 mM EGTA, and 2 mg/ml albumin solution), followed by sonication (pulsed 5x at 10 s per pulse). The samples were then centrifuged at 600  $\times$  g for 5 min to collect nuclei. The supernatant was removed and centrifuged at 1,1000  $\times$  g for 10 min to harvest the mitochondria. The supernatant, which contain cytosol was collected and pulled down by GA affinity beads; it showed mainly  
15           HSP90 $\alpha$  in Lane 3.

          The collected mitochondria were resuspended in lysis buffer and subjected to another cycle of centrifugation for further purification. Lane 4 is the supernatant after second centrifugation. The supernatant was again pulled down with GA affinity beads and showed less HSP90 $\alpha$ .

20           Lane 5 is the purified mitochondrial fraction lysed with lysis buffer B (50 M Tris-HCL, pH7.5, 2 mM EDTA, 100 mM NaCl, 10 mM Na orthovanadate, 1% NP-40) with protease inhibitor cocktail tablet (Roch) and subjected to GA affinity beads. This fraction still contained a trace of HSP90 $\alpha$  but mainly contained VDAC1. This experiment confirmed  
25           the hypothesis that VDAC1 directly binds to GA.

## References

1. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, and Vande Woude GF. (2000). The geldanamycins are potent inhibitors of the  
5 hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. *Cancer Res.* 60: 342–349.
2. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH and Vande Woude GF. (1997). Met and hepatocyte growth factor/scatter factor expression in human gliomas. *Cancer Res.* 57: 5391–5398.
- 10 3. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, and Laterra J. (2002) *In vivo* targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *FASEB J.* 16(1):108–10.
4. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wan LM, Vande Woude GF. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor  
15 (HGF/SF) display antitumor action in animal models. *Proc. Natl. Acad. Sci. U.S.A.* 98(13): 7443–7448.
5. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl F, and Pavletich NP. (1997) Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by antitumor agent. *Cell* 89: 239–250.
- 20 6. Schulte TW, and Neckers LM. (1998). The benzoquinone ansamycin 17-allylamino- 17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. *Cancer Chemother. Pharmacol.* 42: 273–279.
7. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, and Rosen N. (2002). 17-Allylamino-17-  
25 demethoxygeldanamycin induces the degradation of androgen receptor and Her-2/neu and inhibits the growth of prostate cancer xenografts. *Clin. Cancer Res.* 8: 986–993.
8. Brat DJ and Mapstone TB. (2003). Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. *Ann. Intern. Med.* 138: 659–668
9. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, and Comoglio PM. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met  
30 protooncogene. *Cancer Cell* 3: 347–361.
10. Zhang YW, Su Y, Volpert OV, and Vande Woude GF. (2003). Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. *Proc. Natl. Acad. Sci. U.S.A.* 100 (22): 12718–12723.
- 35 11. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, and Simons JW. (2002). Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. *Cancer Res.* 62: 2478–2482.
12. Isaacs JS, Xu W, and Neckers L. (2003). Heat shock protein 90 as a molecular target for cancer therapeutics. *Cancer Cell* 3(3): 213–217.

13. Ochel HJ, Eichhorn K, and Gademann G. (2001). Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. *Cell Stress & Chaperones* 6: 105–112.
14. Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, de Herreros AG, Dunach M, and Neckers LM. (2001). Geldanamycin abrogates ErbB2 association with proteasome resistant  $\beta$ -catenin in melanoma cells, increases  $\beta$ -catenin–E-cadherin association, and decreases  $\beta$ -catenin-sensitive transcription. *Cancer Res.* 61: 1671–1677.
15. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, and Burrows FJ. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature* 425(6956): 407–410.
16. Goetz MP, Toft DO, Ames MM, and Erlichman C. (2003). The HSP90 chaperone complex as a novel target for cancer therapy. *Annals Oncol.* 14: 1169–1176.
17. Workman P, and Maloney A. (2001). HSP90 as a new therapeutic target for cancer therapy: the story unfolds. *Expert Opin. Biol. Ther.* 2(1): 3–24.
18. Egorin MJ, Iagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL. (2002). Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. *Cancer Chemother. Pharmacol.* 49: 7–19.
19. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, and Eiseman JL. (1998). Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. *Cancer Res.* 58: 2385–2396.
20. Munster PN, Basso A, Solit D, Norton L, and Rosen N. (2001). Modulation of HSP90 function by ansamycins sensitize breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. *Clin. Cancer Res.* 1(7): 2228–2236.
21. Birchmeier C, Birchmeier W, Gherardi E, and Vande Woude GF. (2003). Met, metastasis, motility and more. *Nature Reviews Mol. Cell Biol.* 4: 915–925.
22. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, and Salgia R. (2002). Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. *Cytokine Growth Factor Rev.* 13: 41–59.
23. Furge KA, Zhang YW, and Vande Woude GF. (2000). Met receptor tyrosine kinase: enhanced signaling to the adapter proteins. *Oncogene* 19(49): 5582–5589.
24. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, and Comoglio PM. (1998). Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. *Nature* 391: 285–288.
25. Karihaloo A, O'Rourke DA, Nickel C, Spokes K, and Cantley LG. (2001). Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. *J. Biol. Chem.* 276(12): 9166–9173.

26. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, and Testa JR (2001). Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. *Proc. Natl. Acad. Sci. U.S.A.* 98(1): 247–252.
- 5 27. Zhang YW, Wang LM, Jove R, and Vande Woude GF. (2002). Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. *Oncogene* 21: 217–226.
28. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, and Hay N. (2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase *Genes Develop.* 15: 1406–1418.

10

All the references cited above are incorporated herein by reference in their entirety, whether specifically incorporated or not.


Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

15

### ABSTRACT


GAfM drugs that block the uPA-plasmin network and inhibit GBM *in vitro* invasion have the possibility to be used to inhibit tumor invasion *in vivo* at femtomolar concentrations. An effective GA-based treatment would provide an option for treating invasive brain cancers  
5 and potentially could be combined with surgery, conventional chemotherapy, or radiotherapy with the purpose of preventing brain cancer invasion. The novel target of these femtomolar-level drugs may be a key regulatory molecule that promotes or prevents cell motility and invasion.






**Fig. 1**  
uPA assay on MDCK cells

**Fig 2 uPA assay on DBTRG cells**



**Figure 3. Matrigel invasion assay by Geldanamycin**






Fig 4. Geldanamycin (GA) pull-down assays




Figure 5 GA pull-down of porin from mitochondrial enrichment

## **APPLICATION DATA SHEET**

### **Application Information**

**Application Number::**

**Filing Date::**

**Application Type::** Provisional

**Subject Matter::** Utility

**Suggested Classification::**

**Suggested Group Art Unit::**

**CD-ROM or CD-R?::**

**Number of CD Disks::**

**Number of Copies of CDs::**

**Sequence Submission?::**

**Computer Readable Form  
(CFR)?::**

**Number of Copies of CFR::**

**Title::** GELDANAMYCIN AND DERIVATIVES INHIBIT  
CANCER INVASION AND IDENTIFY NOVEL  
TARGETS

**Attorney Docket Number::** 38345-201708

**Request for Early Publication?::** NO

**Request for Non-Publication?::** NO

**Suggested Drawing Figure::**

**Total Drawing Sheets::** 5

**Small Entity?::** YES

**Latin Name::**

**Variety Denomination Name::**

**Petition Included?::**

**Petition Type::**

**Licensed US Govt. Agency::**

**Contract or Grant Numbers::**

**Secrecy Order in Parent Appl.::**

## **Applicant Information**

**Applicant Authority Type::** Inventor  
**Primary Citizenship::**  
**Country::** U.S.A.  
**Status::** Full Capacity  
**Given Name::** Qian  
**Middle Name::**  
**Family Name::** XIE  
**Name Suffix::**  
**City of Residence::** Grand Rapids  
**State or Province of Residence::** Michigan  
**Country of Residence::** U.S.A.  
**Street of Mailing Address::**  
**City of Mailing Address::** Grand Rapids  
**State or Province of Mailing Address::** Michigan  
**Country of Mailing Address::** U.S.A.  
**Postal or Zip Code of Mailing Address::**

**Applicant Authority Type::** Inventor  
**Primary Citizenship::**  
**Country::** U.S.A.  
**Status::** Full Capacity  
**Given Name::** David  
**Middle Name::**  
**Family Name::** WENKERT  
**Name Suffix::**  
**City of Residence::** East Lansing  
**State or Province of Residence::** Michigan  
**Country of Residence::** U.S.A.  
**Street of Mailing Address::**

**City of Mailing Address::** East Lansing

**State or Province of Mailing Address::**

**Country of Mailing Address::** U.S.A.

**Postal or Zip Code of Mailing Address::**

**Applicant Authority Type::** Inventor

**Primary Citizenship::**

**Country::**

**Status::**

**Given Name::** Yuehai

**Middle Name::**

**Family Name::** SHEN

**Name Suffix::**

**City of Residence::**

**State or Province of Residence::**

**Country of Residence::**

**Street of Mailing Address::**

**City of Mailing Address::**

**State or Province of Mailing Address::**

**Country of Mailing Address::**

**Postal or Zip Code of Mailing Address::**

## **Correspondence Information**

**Correspondence Customer Number::** 26694

**Phone Number::** (202) 344-4000

**Fax Number::** (202) 344-8300

**E-Mail Address::**



## **Representative Information**

**Representative Customer  
Number::** 26694

## **Assignee Information**

**Assignee Name::** Van Andel Research Institute  
**Street of Mailing Address::** 333 Bostwick NE  
**City of Mailing Address::** Grand Rapids  
**State or Province of Mailing  
Address::** Michigan  
**Country of Mailing Address::** U.S.A.  
**Postal or Zip Code of Mailing  
Address::** 49503